The aim of this study was to evaluate plasma and synovial fluid concentrations of the non-steroidal anti-inflammatory drug nimesulide and its major metabolite (hydroxynimesulide, M1), after a single 100 mg dose of nimesulide and a repeated (14 day) administration, 100 mg twice a day, in patients with osteoarthritis of the knee and joint effusion. Nimesulide was rapidly absorbed in plasma and distributed in synovial fluid. On day 1, effective concentrations were present 30 min after the first dose and on day 14, the synovial fluid concentration of nimesulide was significantly higher than that measured on day 1; no accumulation was observed in plasma. After 14 days of treatment, both the plasma and synovial fluid concentrations of M1 were significantly higher than those measured on day 1. These data may help to explain the rapid onset of the analgesic effect of nimesulide demonstrated in several clinical conditions, including painful osteoarthritis.
Introduction
Nimesulide (4′-nitro-2′-phenoxy-methanesulphonanilide) is a non-steroidal anti-inflammatory drug (NSAID) belonging to the sulphonanilide class, which preferentially inhibits cyclooxygenase-2 (COX-2) and is characterized by a multifactorial mode of action. 1 At the recommended daily dosage of 100 mg twice a day, nimesulide was at least equivalent to or more effective than other NSAIDs in relieving inflammation and pain in a variety of conditions. 1 -3 In particular, nimesulide has been demonstrated to be highly effective in providing relief from the pain associated with osteoarthritis (OA). 4 In a recent study in patients with OA of the knee, nimesulide proved to be more effective than celecoxib and rofecoxib by providing more rapid pain relief. 5 M Bianchi, P Ferrario, P Balzarini et al.
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The pharmacokinetic profile of nimesulide and its main metabolite, 2-(4′-hydroxyphenoxy)-4-nitro methanesulphonanilide (hydroxynimesulide or M1) has been extensively described. 6 -8 Pharmacological tests showed that M1 maintains anti-inflammatory and analgesic properties, although to a lesser extent compared to the parent drug. 6, 9 However, little is known about the diffusion at articular sites of nimesulide and M1, after oral administration of the parent drug. 10 Recent findings showed the ability of nimesulide to inhibit prostaglandin E 2 (PGE 2 ) at joint level in patients with arthritis; 11 however, the concentrations of nimesulide and its main metabolite in the joint cavity of patients with OA were not known. As these structures are a major site of action for a NSAID, its concentration in synovial fluid should be considered an important determinant of clinical response. 12 For all these reasons, it was considered of interest to evaluate plasma and synovial fluid concentrations of nimesulide and M1 after both a single 100 mg dose of nimesulide and a repeated (14 day) administration (100 mg twice a day) in patients with OA of the knee and synovial fluid effusion.
Patients and methods

PATIENTS
Men and women out-patients, aged 18 years or older, were eligible to participate in the study if they fulfilled the American College of Rheumatology (ACR) criteria for a diagnosis of OA, 13 and the knee designated as the 'study joint' presented synovial fluid effusion, and was the main source of pain in the lower extremity. Inclusion criteria included a minimum visual analogue score (VAS) of 40 mm for the basal assessment of pain connected with walking. Patients were excluded if they had a concurrent arthritic disease or values of laboratory results outside the normal reference range or a history of allergy or hypersensitivity to nimesulide. Non-degenerative joint diseases (e.g. infectious, microcrystalline) were also exclusion criteria. All patients gave their written informed consent to the study. The trial was conducted in the Rheumatology Unit of the Ospedale di Circolo e Fondazione Macchi, Varese, Italy in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. Approval for the study protocol was given by the Ethics Committee of the A.O. Ospedale di Circolo e Fondazione Macchi.
METHODS
After a drug-washout period of 48 h, the patients were treated with nimesulide tablets, 100 mg twice a day, for 14 days. Synovial fluid and blood samples were drawn at baseline, 30 min after the first dose of nimesulide (100 mg tablet), and at the end of the treatment period (30 min after the intake of the last tablet of nimesulide, on the morning of day 14 of the study). Freshly aspirated synovial fluid (3.0 ml) was collected in tubes containing ethylenediaminotetraacetic acid (EDTA). The fluid was centrifuged for 10 min at 1500 g at 4°C, and the supernatant was collected and frozen at -20°C until assay. Blood was collected in tubes containing EDTA, and the plasma obtained by centrifugation (10 min at 1500 g at 4°C) was frozen at -20°C until assay.
Nimesulide and M1 concentrations in plasma and synovial fluid were measured by high performance liquid chromatography (HPLC) with UV detection, using a method previously described and validated. 14 This method was found to be specific and linear up to 10 000 ng/ml in the samples. The lower limit of quantification for both nimesulide and M1 was 25 ng/ml. Samples of nimesulide and M1 were obtained from Concentrations of nimesulide and its metabolite after oral administration Helsinn Healthcare (Pambio-Noranco, Switzerland). The internal standard, 2′-(cyclohexyloxy)-4′-nitrophenyl methanesulphonanilide NS398 was purchased from Inalco (Milan, Italy) while disodium orthophosphate dodecahydrate, sodium citrate and orthophosphoric acid, all of analytical grade, were obtained from Sigma (Milan, Italy). Methanol and acetonitrile (LC grade) were purchased from Merck (Darmstadt, Germany). Heparin was obtained from Parke-Davis (Milan, Italy). Disposable C 18 100 mg/1 ml cartridges for solid phase extraction (SPE) were produced by International Sorbent Technology (Hengoed, Mid Glamorgan, UK).
A Millipore Waters Model 590 liquid chromatograph (Waters, Milford, MA, USA) with a variable wavelength LC75 Spectrophotometric UV detector (PerkinElmer, Norwalk, CT, USA) was employed. The injection valve was a model 7125 Rheodyne (Cotati, CA, USA). The system was connected to a Hitachi-Merck D-2000 chromato-integrator (Merck). A Waters Symmetry column, C 18 3.5 µm (150 × 4.6 mm internal diameter), coupled to a Waters Sentry Symmetry C 18 guard column (10 × 2.1 mm internal diameter) was operated at room temperature. The mobile phase was acetonitrile : 50 mM sodium citrate buffer, pH 3.00 (53 : 47). The buffer was prepared fresh daily by dissolving 16.8 g of citric acid and 2.66 g of sodium hydroxide in 1000 ml of bidistilled water and adjusting the solution to pH 3.00 with orthophosphoric acid. The flow rate was 1.1 ml/min and the elution was monitored at 240 nm.
STATISTICAL ANALYSIS
The data were analysed by one-way ANOVA. P-values < 0.05 were considered statistically significant.
Results
A total of 10 patients, one male and nine females, was enrolled. The mean age was 72.3 ± 2.9 (mean ± SEM). Figure 1 shows 
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the mean plasma and synovial fluid concentrations of nimesulide on day 1 and day 14. The ratios of the concentrations of nimesulide in synovial fluid to the concentrations in plasma were calculated and mean values on day 1 and on day 14 were 0.17 ± 0.03 and 0.46 ± 0.03, respectively. The mean plasma concentrations of nimesulide on day 1 and on day 14 were similar: 2.0 (6.5 µM) ± 0.15 µg/ml and 2.5 (8.1 µM) ± 0.20 µg/ml, respectively. These data demonstrate that nimesulide does not accumulate in plasma. The mean synovial concentration of nimesulide on day 14 was significantly higher (P < 0.05) than that measured on day 1; 0.34 (1.1 µM) ± 0.2 µg/ml and 1.2 (3.8 µM) ± 0.16 µg/ml for days 1 and 14, respectively, suggesting that nimesulide takes time to reach a steady state in the synovial fluid.
The mean plasma and synovial fluid concentrations of M1 on days 1 and 14 are reported in Table 1 . The ratios of concentrations of M1 in synovial fluid to the concentrations in plasma on day 1 and on day 14 were 0.25 ± 0.03 and 0.59 ± 0.04, respectively. It should be noted that some results for the patients were below the detection limit (25 ng/ml) of the assay, and therefore could not be considered in the analysis. The ratios between nimesulide and its main metabolites M1 in plasma and synovial fluid on the first and the last day of treatment were also calculated and reported in Table 2 . These data are largely related to the marked increase in M1 synovial fluid concentrations following repeated administration of nimesulide.
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A considerable number of studies have demonstrated the efficacy and tolerability of oral nimesulide in patients with painful OA. 15 -21 Evidence is available on the ability of nimesulide to inhibit PGE 2 at the joint level in patients with arthritis. 11 To the authors' knowledge, however, this is the first study to look at the concentrations of nimesulide in the joints of patients with OA and investigate the levels of nimesulide achieved in plasma and synovial fluid of OA patients following the administration of a single or repeated dose of this NSAID. In 1990, the synovial fluid concentrations of nimesulide were evaluated in patients with rheumatoid arthritis treated with nimesulide, 100 mg tablets twice daily, for 7 days. 10 Three and 12 h after the last dose of the drug, the synovial fluid : plasma concentration ratios were 0.44 and 0.54, respectively. A comparison between these data and the present results suggests that there was no significant difference between the ability of nimesulide to penetrate into the joints of patients with rheumatoid arthritis or OA, after repeated administration of the drug. In both cases, nimesulide appears to diffuse quickly into the synovial fluid after oral administration. In the present study, as expected, the drug concentrations in the synovial fluid were lower than in plasma and were about 48% of the concomitant plasma concentration when the concentration plateau had definitely been achieved (i.e. 1.2 µg/ml in synovial fluid versus 2.5 µg/ml in plasma on day 14). In light of the short plasma half-life of nimesulide (1.8 -4.7 h), it was assumed that the concentration plateau had been reached after 14 days. This ratio appears to be in agreement with those observed for other NSAIDs in patients with rheumatic diseases, although a direct comparison with other drugs is difficult due to the different patients' conditions in the various trials. 22 -24 The degree of accumulation of nimesulide in plasma was minimal, consistent with the pharmacokinetics of this drug. 6 With reference to the nimesulide concentrations in the synovial fluid, the present findings show that a repeated administration of the drug for 2 weeks leads to a significant increase in drug concentration in the joint compared with the levels reached following the administration of a single dose on day 1.
Inhibition of COX, and therefore prostaglandin production, is the common mechanism of action of NSAIDs. In particular, inhibition of COX-2 activity represents the most likely mechanism of action for NSAID-mediated analgesia. 25, 26 Even though it is well known that nimesulide, beyond COX-inhibition, exerts a number of pharmacological actions relevant to the reduction of inflammatory pain, 1 -3 it is 27 on the potencies of a series of NSAIDs, including nimesulide, as inhibitors of COX-1 and COX-2, it is evident that after oral treatment in patients with OA, nimesulide is rapidly able to reach (i.e. within 30 min of administration of the first dose) effective concentrations (i.e. able to produce 80% inhibition of COX-2) in plasma. The drug concentrations measured in the synovial fluid, 30 min after the first administration of nimesulide, on the other hand, can be associated with an inhibition of COX-2 greater than 50% when calculated with reference to the standard William Harvey Human Modified Whole Blood Assay (WHMA). This concentration suggests that a reduction of synovial inflammation induced by a local action of the drug may be involved in the analgesic effect of nimesulide in patients with OA.
The results from this study demonstrate that after 2 weeks of treatment the concentrations of M1 proved to be significantly higher than those measured on day 1, both in plasma and in the synovial fluid. These data suggest that after repeated administration of the parent drug, M1 might participate in mediating the pharmacological effects of nimesulide at least in the joint, where its increase is particularly evident.
In conclusion, the present findings are consistent with the efficacy and the fast onset of action demonstrated by nimesulide in patients with OA and other kinds of inflammatory pain. 2, 5, 28, 29 Moreover, they provide scientific evidence relating to the mechanisms underlying the rapid analgesic action of this NSAID, suggesting it may also be related to the modulation of inflammatory mediators at the joint level.
